Styrylboronic Acid

Styrylboronic Acid

SCHEMBL144461

OB(O)C=Cc1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 5/20 1.00
MGLL Q99685 1/20 0.75
MAOB P27338 2/20 0.50
CA2 P00918 2/20 0.48
ARG2 P78540 1/20 0.46
ALDH1A1 P00352 2/20 0.46
LMNA P02545 2/20 0.46
HDAC3 O15379 2/20 0.46
HDAC4 P56524 2/20 0.46
HDAC1 Q13547 2/20 0.46
HDAC2 Q92769 2/20 0.46
HDAC8 Q9BY41 2/20 0.46
HDAC6 Q9UBN7 2/20 0.46
TNKS O95271 1/20 0.46
HCAR2 Q8TDS4 1/20 0.46
HDAC7 Q8WUI4 1/20 0.46
HDAC10 Q969S8 1/20 0.46
HDAC11 Q96DB2 1/20 0.46
TNKS2 Q9H2K2 1/20 0.46
HDAC9 Q9UKV0 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Styrylboronic Acid SCHEMBL144460 1.00 CA1 (1.00) CA1MGLLMAOBCA2ARG2
Styrylboronic Acid SCHEMBL4168786 1.00 CA1 (1.00) CA1MGLLMAOBCA2ARG2
Styrylboronic Acid SCHEMBL4390084 0.97 CA1 (0.95) CA1MGLLMAOBCA2ARG2
Styrylboronic Acid SCHEMBL28579652 0.87 CA1 (0.76) CA1MGLLMAOBCA2ARG2
SCHEMBL2910475 0.86 CA1 (1.00) CA1MGLLMAOBCA2ARG2
SCHEMBL12260418 0.86 CA1 (1.00) CA1MGLLMAOBCA2ARG2
SCHEMBL8011423 0.84 CA1 (0.73) CA1MGLLMAOBALDH1A1LMNA
(Z)-1,2-Diphenylethene SCHEMBL29134000 0.76 MAOB (0.69) CA1MAOBALDH1A1LMNAHDAC3
SCHEMBL23044739 0.75 CA1 (0.61) CA1MGLLMAOBCA2MAPT
SCHEMBL13204210 0.75 CA1 (0.61) CA1MGLLCA2TRPA1NFE2L2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1590 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250029794-A1 GEL ELECTROLYTE SUPERCAPACITOR IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) 2025-01-23 US claimed
CN-114502603-B Degradable polymeric material 南洋理工大学 2024-12-03 CN claimed
US-12142425-B2 Supercapacitor with gel electrolyte for electrochemical double-layer energy storage IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) 2024-11-12 US claimed
WO-2024099368-A1 PEPTIDE TAGS, COMPOSITIONS AND METHODS FOR SITE-SPECIFIC PROTEIN CONJUGATION Westlake University (CN) 2024-05-16 WO claimed
US-20230372747-A1 PERSONAL PROTECTIVE ANTI-VIRAL FACE MASK IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. 2023-11-23 US claimed
US-20230317379-A1 SUPERCAPACITOR WITH GEL ELECTROLYTE FOR ELECTROCHEMICAL DOUBLE-LAYER ENERGY STORAGE IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) 2023-10-05 US claimed
CN-116675687-A Dihydropyrimidine derivative containing carboxylic acid and preparation method and application thereof 山东大学 2023-09-01 CN claimed
CN-116655459-A Synthetic method for selectively synthesizing 4-aryl-2-hexanone 河南大学 2023-08-29 CN claimed
WO-2022076152-A2 PERSONAL PROTECTIVE ANTI-VIRAL FACE MASK IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) 2022-04-14 WO claimed
WO-2021071432-A1 DEGRADABLE POLYMERIC MATERIALS NANYANG TECHNOLOGICAL UNIVERSITY (SG) 2021-04-15 WO claimed
JP-2011508908-A 2011-03-17 JP claimed
EP-2231207-A1 COATING SOLUTIONS COMPRISING SEGMENTED INTERACTIVE BLOCK COPOLYMERS Bausch & Lomb Incorporated (US) 2010-09-29 EP claimed
US-20100040538-A1 Polymer Systems for Lung Volume Reduction Therapy CANADIAN IMPERIAL BANK OF COMMERCE (CA) 2010-02-18 US claimed
WO-2009085756-A1 COATING SOLUTIONS COMPRISING SEGMENTED INTERACTIVE BLOCK COPOLYMERS BAUSCH & LOMB INCORPORATED (US) 2009-07-09 WO claimed
WO-2009085754-A1 SEGMENTED INTERACTIVE BLOCK COPOLYMERS BAUSCH & LOMB INCORPORATED (US) 2009-07-09 WO claimed
US-20090168012-A1 COATING SOLUTIONS COMPRISING SEGMENTED INTERACTIVE BLOCK COPOLYMERS BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC. (CA) 2009-07-02 US claimed
US-20090171027-A1 SEGMENTED INTERACTIVE BLOCK COPOLYMERS BAUSCH & LOMB INCORPORATED 2009-07-02 US claimed
EP-2059227-A2 POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY Aeris Therapeutics, Inc. (US) 2009-05-20 EP claimed
WO-2008039827-A2 POLYMER SYSTEMS FOR LUNG VOLUME REDUCTION THERAPY AERIS THERAPEUTICS, INC. (US) 2008-04-03 WO claimed
US-20020045775-A1 Heterogeneously catalyzed process for cross coupling alkenyl halides with boronic acids MERCK & CO., INC. 2002-04-18 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100040538-A1 Polymer Systems for Lung Volume Reduction Therapy GFER, MUC1, CTH CA1 1918/4885MGLL 2208/4885MAOB 2732/4885
US-20020045775-A1 Heterogeneously catalyzed process for cross coupling alkenyl halides with boronic acids BRPF1, BRD2, BRD7 CA1 3852/4885MGLL 626/4885MAOB 256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.